Recent randomized trials in Japan have proved that S-1, a novel fluoropyrimidine derivative, and cisplatin are the most promising agents. However, both the efficacy and toxicity of a given regimen ...

Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change ...

This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens. As we learn how to incorporate ...

We describe a 38-year-old man with a resectable metastasis from hereditary nonpolyposis colorectal cancer, with indication of neoadjuvant chemotherapy and a family history of fluoropyrimidine ...